

# IMVEXXY® Update

April 8, 2019



TherapeuticsMD®

*For Her. For Life.*

TherapeuticsMD.com

# Forward-Looking Statements

This presentation by TherapeuticsMD, Inc. (referred to as “we” and “our”) may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of our managerial experience and perception of historical trends, current conditions, expected future developments and other factors we believe to be appropriate.

Forward-looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which may be outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as our current reports on Form 8-K, and include the following: our ability to maintain or increase sales of our products; our ability to develop and commercialize IMVEXXY<sup>®</sup>, ANNOVERA<sup>™</sup>, BIJUVA<sup>™</sup> and our hormone therapy drug candidates and obtain additional financing necessary therefor; whether we will be able to comply with the covenants and conditions under our term loan agreement; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of our current or future approved products or preclude the approval of our future drug candidates; the length, cost and uncertain results of future clinical trials; the ability of our licensees to commercialize and distribute our product and product candidates; our reliance on third parties to conduct our manufacturing, research and development and clinical trials; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of our common stock and the concentration of power in our stock ownership.

This non-promotional presentation is intended for investor audiences only.

# Strong Imvexxy® Launch

## IMVEXXY (estradiol vaginal inserts) Launch Metrics

Total paid scripts dispensed to patients <sup>1</sup> (since launch through March 31, 2019)	~137,600
Total paid scripts (March 1-31, 2019)	~28,100
Total patients (since launch through March 31, 2019)	~44,700
Total prescribers <sup>2</sup> (since launch through March 31, 2019)	~10,100

## Comparison of Average Weekly & Daily Script Volume

(Average Weekly Volume: TRx for month / # days in month \* 7 days)

	For 28 Days in Feb. 2019	For 31 Days in Mar. 2019
Average weekly volume	~5,900	~6,300
Average daily volume	~840	~900


<sup>1</sup>Total prescription data is based on IQVIA prescriber level data plus additional unique patients identified through utilization of our affordability program. This includes a one week estimation for the lag in reporting retail data, which can cause minor fluctuations in historical comparisons.

<sup>2</sup>Total Unique Prescribers that have sent a prescription to a pharmacy for at least 1 patient for IMVEXXY.

# Successful Launch Execution

## IMVEXXY TRx Launch Comparison

- IMVEXXY continues to grow both weekly average volume and daily average volume for March (31 day month) vs February (28 day month)
- Average daily volume for 31 days in March 2019 increase to ~900 from ~840 for the 28 days in February 2019



\*Month 9 for IMVEXXY is March 2019

### References:

- Total prescription data is based on IQVIA prescriber level data plus additional unique patients identified through utilization of our affordability program.
  - Ospheña and Intrarosa sourced is Symphony Health Integrated Dataverse.
  - Vagifem sourced from IQVIA National Prescriber Level Data.
- All trademarks are the property of their respective owners.

**TherapeuticsMD<sup>®</sup>**  
*For Her. For Life.*

# Strong Patient Adherence & Compliance

through March 31, 2019

## IMVEXXY Patient Compliance<sup>1,2</sup>

Month Initial Prescription Filled	Average # Fills for those Patients	Maximum Allowable Fills Given the Month of Initial Fill
February 2019	1.8 Fills	2 Fills
January 2019	2.5 Fills	3 Fills
December 2018	3.0 Fills	4 Fills
November 2018	3.7 Fills	5 Fills
October 2018	4.1 Fills	6 Fills
September 2018	4.7 Fills	7 Fills
August 2018	6.0 Fills	8 Fills

Example of calculation: For patients who filled their initial prescription in November 2018, each of those patients averaged 3.7 fills from November 2018 through March 2019

**Average fills for all patients through March 31, 2019 = 3.07<sup>3</sup>**

<sup>1</sup>Average number of fills per patient is the average number of fills per patient grouped by their initial month on therapy.

<sup>2</sup>Total prescription data is based on IQVIA prescriber level data plus additional unique patients identified through utilization of our affordability program.

<sup>3</sup>Average number of fills for all patients is calculated as Total Rx / Total Patients.